We apply machine-learning techniques to predict drug approvals using drug-development and clinical-trial data from 2003 to 2015 involving several thousand drug-indication pairs with over 140 features across 15 disease groups. To deal with missing data, we use imputation methods that allow us to fully exploit the entire dataset, the largest of its kind. We show that our approach outperforms complete-case analysis, which typically yields biased inferences. We achieve predictive measures of 0.78, and 0.81 AUC ("area under the receiver operating characteristic curve," the estimated probability that a classifier will rank a positive outcome higher than a negative outcome) for predicting transitions from phase 2 to approval and phase 3 to approval, respectively. Using five-year rolling windows, we document an increasing trend in the predictive power of these models, a consequence of improving data quality and quantity. The most important features for predicting success are trial outcomes, trial status, trial accrual rates, duration, prior approval for another indication, and sponsor track records. We provide estimates of the probability of success for all drugs in the current pipeline.
Introduction
While many recent medical breakthroughs such as immuno-therapies, gene therapies, and gene-editing techniques offer new hope for patients, they have also made biomedical innovation riskier, and more complex and expensive. These breakthroughs generate novel therapies for investigation, each of which requires many years of translational research and clinical testing, costing hundreds of millions to billions of dollars and yet often face a high likelihood of failure (Fernandez, Stein, & Lo, 2012) . In fact, drug development productivitythe ratio of the number of new drugs approved to R&D spending each year-has declined steadily over the past 50 years despite scientific and technical progress. This phenomenon, which Scannell, Blanckley, Boldon, and Warrington (2012) termed "Eroom's Law," as the reverse of Moore's Law, suggests that the cost of developing new drugs has doubled approximately every nine years since the 1950s. In the face of multiple uncertainties, the need to evaluate drug candidates better and allocate capital to high-potential opportunities more efficiently has only intensified.
To address these needs, in this article we apply machine-learning techniques to predict the outcomes of randomized clinical trials. Machine learning is an interdisciplinary field focused on tackling pattern recognition problems and building predictive models to make datadriven decisions, which is well-suited for this context. Successful applications of these techniques have already revolutionized a number of industries (e.g., advertising, marketing, finance and insurance, oil and gas exploration) and are poised for even greater impact via autonomous vehicles, facial-recognition authentication, and general-purpose robotics. Predictive models for assessing the probability of approval of drug candidates in two scenarios: (1) after phase 2 testing, and (2) after phase 3 testing.
To the best of our knowledge, our study is the largest of its kind. We construct two datasets, one for each scenario, from two proprietary pharmaceutical pipeline databases, Pharmaprojects and Trialtrove provided by Informa ® (Informa, 2016) . The phase-2-toapproval dataset includes more than 6,000 unique drugs for 288 indications and over 14,500 phase 2 trials, and the phase-3-to-approval dataset contains more than 1,400 unique drugs for 253 indications and over 4,500 phase 3 trials. These data cover over 15 indication groups.
In contrast, most published research on drug approval prediction have very small sample HDSR Issue 1
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Machine Learning Predictions of Drug Approvals Page 4 of 44 © 2019 by Lo, Siah, and Wong, All Rights Reserved sizes, are concentrated on specific therapeutic areas, and involve only one or a small number of predictive factors: Malik et al. (2014) examined the trial objective responses of 88 anticancer agents in phase 1; Goffin, Baral, Tu, Nomikos, and Seymour (2005) studied the tumor response rates of 58 cytotoxic agents in 100 phase 1 trials and 46 agents in 499 phase 2 trials; El-Maraghi and Eisenhauer (2008) looked at the objective responses of 19 phase 2 anticancer drugs in 89 single agent trials; Jardim, Groves, Breitfeld, and Kurzrock (2017) examined the response rates of 80 phase 3 oncology drugs to identify factors associated with failures; and DiMasi et al. (2015) analyzed 62 cancer drugs and proposed an approved new drug index (ANDI) algorithm with four factors to predict approval for lead indications in oncology after phase 2 testing (see Supplementary Materials H for a comparison of our analysis to theirs).
Another key difference in our approach is that we deal with missing data using statistical imputation methods. We explore four common approaches to "missingness" and demonstrate their advantages and disadvantages over discarding incomplete cases. With the FDA Amendments Act of 2007, drug and clinical trial data collection has been rapidly expanding, but these data are often sparse, and our dataset is no exception. Related studies (e.g., DiMasi et al., 2015) have typically used only complete-case observations-discarding clinical trials with any missing information-which typically eliminates large portions of the data and may also lead to certain biases.
We use machine-learning techniques to form our predictions, including cross-validation for training and a held-out testing set for performance evaluation, and use the standard "area under the receiver operating characteristic curve" (AUC) metric to measure model Table 1 and Supplementary Materials A. In general, each dataset may be partitioned into two disjoint subsets: one with samples that have known outcomes, and another with samples that are still in the pipeline at the time of snapshot of the databases (that is, the outcomes are unknown). To provide intuition for the characteristics of the samples, we describe key summary statistics of each subset.
The P2APP dataset consists of 6,344 drug-indication pairs that have ended phase 2 testing; that is, there are no phase 2 trials in progress or planned in the database. The phase 2 trials in this dataset range from August 8, 1990 to December 15, 2015. In our sample, 4,812 pairs have known outcomes, while 1,532 pairs are still in the pipeline. In the subset with known outcomes, we define the development statuses of suspension, termination, and lack of development as "failures" (86.8%), and registration and launch as "successes" or approvals (13.2%). The P3APP dataset consists of 1,870 pairs that have ended phase 3 testing, of which 1,610 pairs have known outcomes, while 260 pairs are still in the pipeline. For those pairs with known outcomes, we define "failures" (59.1%) and "successes" (40.9%) in the same can include drug development programs that are terminated due to factors unrelated to the performance of the drug (e.g., market conditions, business decisions). In Section 3 Results, we find that this outcome variable has significant associations with trial performance and other factors.
The datasets cover 15 indication groups: alimentary, anti-infective, anti-parasitic, blood and clotting, cardiovascular, dermatological, genitourinary, hormonal, immunological, musculoskeletal, neurological, anti-cancer, rare diseases, respiratory, and sensory products.
Anti-cancer agents make up the largest subgroup in P2APP, and the second largest in P3APP (see Table 3 ). Industry-sponsored trials dominate both datasets (see Table 4 ). In aggregate, we observe a decreasing trend in success rates over five-year rolling windows from 2003 to 2015 (see Fig 2) .
To the best of our knowledge, this sample is the largest of its kind. All prior published research in this literature involved fewer than 100 drugs or 500 trials (DiMasi et al., 2015; El-Maraghi & Eisenhauer, 2008; Goffin et al., 2005; Malik et al., 2014) . In addition, our datasets cover a diverse set of indication groups, as opposed to a single area such as oncology. Family of proteins in the body whose activity is modified by the drug, resulting in a specific effect.
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Missing data
Prior to the 2007 FDA Amendments Act (FDAAA), it was not uncommon for investigators to release only partial information about pipeline drugs and clinical trials to protect trade secrets or simply because there was no incentive to do more. Even today, some investigators still do not adhere to the FDAAA-mandated registration policy or submit adequate registrations. Therefore, all historical drug development databases have missing data. We note that the "missingness" here is largely related to the post-study reporting of clinical trial data as opposed to in-trial data missingness (e.g., censorship of panel data due to patients terminating trial participation prematurely). In the former case, the data (e.g., trial duration, trial outcomes) are usually available to the investigators but may not be released publicly, and are thus considered "missing" from our standpoint. Therefore, our dataset may be Table 5 , and Table 6 summarize the patterns of missingness in our dataset (we exclude pipeline drug-indication pairs here because their outcomes are still pending). The missing data patterns are multivariate. When conditioned on the latest level of development, for any indication, we find that successful drugs generally have lower levels of missingness compared to failed drugs. For instance, in the P2APP dataset, 61% of failed drugs have an unknown medium, while only 15% of approved drugs are missing this feature. We also observe that completed trials tend to have greater levels of missingness than terminated trials. Between two datasets, we find that the P3APP dataset, which focuses on phase 3 drugs and trials, generally has less missing data for both drug and trial features than the P2APP dataset which focuses on phase 2 drugs and trials. This is expected since phase 3 trials are primarily used to support registration filings. Missing data may be classified into three categories (Rubin, 1976) : missing completely at random (MCAR), missing at random (MAR), and missing not-at-random (MNAR). MCAR refers to data that are missing for reasons entirely independent of the data; MAR applies when the missingness can be fully accounted for by the observed variables; and MNAR refers to situations when neither MCAR nor MAR is appropriate, in which case the probability of missingness is dependent on the value of an unobserved variable (Van Buuren, 2012) . See Supplementary Materials B for the precise definitions of each type of missingness.
If the missingness is MCAR, the observed samples can be viewed as a random subsample of the dataset. Consequently, using listwise deletion should not introduce any bias. While convenient, this assumption is rarely satisfied in practice. In most drug-development databases, failed drugs are more likely to have missing features than successful drugs (see Table 5 ). Clearly, MCAR does not hold.
Applying listwise deletion when the missingness is not MCAR can lead to severely biased estimates. Moreover, given the nature of drug-development reporting, a large portion of the original data may be discarded if many variables have missing values. For these reasons, the listwise-deletion approach adopted by DiMasi et al. (2015) and others is less than ideal.
Given only the observed data, it is impossible to test for MAR versus MNAR (Enders, 2010) .
However, our knowledge of the data-collection process suggests that MAR is a plausible starting point, and we hypothesize that the missingness in drug and trial features is mainly Table   5 and Table 6 support this approach, as the missingness proportions for some features differ greatly depending on the outcome.
Our assumption of MAR is consistent with the data-collection methodology in the Informa ® databases. Drug profiles are built up over time in Pharmaprojects. As a drug advances to later phases, information about its characteristics becomes more readily available because investigators release more data about pipeline drugs after each phase of clinical testing.
Informa ® inputs this information into its databases as they become available in the public domain or through primary research. Approved drugs are more likely to have more complete profiles, while information about failed drugs tends to stay stagnant because no further studies are conducted. It is very plausible that the MAR nature of our datasets is an artifact of data collection, and by extension, so are similar pharmaceutical datasets extracted from the public domain and maintained in the same fashion. Originally intended to track drug and trial activities, Pharmaprojects and Trialtrove are not structured to keep track of information updates over time since there was no use for it. Without timestamps of the updates, we are not able to eliminate the MAR artifact from our datasets.
In our analysis, we impute the missing data under the more plausible MAR assumption to obtain complete datasets. In contrast to listwise deletion, we fill in missing values using information in the observed variables. This allows us to utilize data that would otherwise be discarded. Thereafter, we can apply all the usual statistical estimators to this imputationcompleted data. 
Methods
Our analysis consists of two parts that we perform in R version 3.2.3. First, we impute missing values to generate complete datasets. Next, we apply a range of machine-learning algorithms to build predictive models based on the imputed data. Illustration of the specific components of our analysis appear in Fig 5 . We formulate our two scenarios as supervised bipartite ranking problems, where the goal is to predict the outcome-success or failure-of a drug-indication pair given a set of input features. Initially, we split each dataset into training and testing sets. For each scenario, we train various classifiers based on the corresponding training set, and compute the expected error of our predictive models by testing them on the held-out testing set.
We create feature matrices from the datasets by representing drug and trial features for each drug-indication pair as vectors (see Fig 6) . Drug-indication pairs associated with multiple trials are represented by the same number of feature vectors, e.g., a pair with two trials has two rows. We give a concrete example in Fig 6. Consider the drug-indication pair Analiptindiabetes type 2 in the P2APP dataset. We represent it using two vector rows since it has two phase 2 trials in Trialtrove. Note that the feature matrix is incomplete due to missing drug We also construct a column vector of labels, which contains the outcomes of the drug-indication pairs. Labels are not available for pipeline drug-indication pairs because they are still in development and their outcomes are still uncertain, hence these observations are not used to train our classifiers. However, with the trained classifiers, we can generate predictions for pipeline data.
We split each dataset (excluding pipeline drugs-indication pairs) into two disjoint sets, one training set and one testing set, and form feature matrices for both according to the drugindication pairs in each set. The testing sets serve as out-of-sample datasets to evaluate our models. Therefore, we mask their outcomes (that is, we treat them as unknown) and access them only at the very end to check our performance. To deal with missing data in both training and testing sets, we consider listwise deletion and four statistical imputation techniques commonly used in social science research and biostatistics: unconditional mean imputation, k-nearest neighbor (kNN) imputation, multiple imputation (MI), and decision-tree algorithms (see Supplementary Materials C for details). We follow best practices of the missing-data literature by including as many relevant auxiliary variables as possible, as well as all variables used in subsequent models (Collins, Schafer, & Kam, 2001; Enders, 2010; Rubin, 1996; Schafer & Graham, 2002) . This makes the assumption of MAR more plausible in our datasets, and helps to reduce bias in subsequent analyses (Schafer, 1997) . In particular, it is necessary to include our target variable-the drug-indication development status-in our imputation model because we hypothesize that missingness is mainly accounted for by it. This is not an issue for the training sets. However, the outcomes in the testing sets are masked, and not supposed to be known. Therefore, we treat the testing set outcomes as though they were missing and impute them together with all the other missing features. After imputation, we discard the imputed testing-set outcomes, and use only the imputed feature values for predictions. We do the same when evaluating pipeline datasets.
With respect to the machine-learning algorithm, we explore several linear and non-linear classifiers commonly used in this literature: penalized logistic regression (PLR), random forests (RF), neural networks (NN), gradient boosting trees (GBT), support vector machines with radial basis functions (SVM), and decision trees C5.0. We implement the first five algorithms using the scikit-learn package in Python (Pedregosa et al., 2011) and the sixth using the C50 package in R (Kuhn, Weston, Coulter, & Quinlan, 2014 Fig 6) . Both rows are used as training examples, and each is weighted equally during training (0.5, since there are two trials in total). To obtain predictions for a drugindication pair, we average the output probabilities and scores of the corresponding feature vector rows that are used as inputs to the classifier.
All machine-learning algorithms have hyper-parameters that affect the flexibility of the model and must be tuned to each dataset to optimize goodness of fit. Poorly-chosen hyperparameters can lead to overfitting (attributing signal to noise) or underfitting (attributing noise to signal). We tune our parameters using k-fold cross-validation (with k = 5 or 10, depending on the sample size). Since the cross-validation process should emulate the testing process as closely as possible, we include imputation in the cross-validation loop as well. We split the training set into validation and non-validation folds. Then we treat validation fold outcomes as missing, and impute them as we would for a testing set. From here, we ignore the imputed validation fold outcomes and proceed with the standard validation process.
In the final step, we test the trained classifiers on the unseen testing sets for out-of-sample model validation. This gives the expected performance of our predictive models for each of the scenarios, using the standard AUC metric to measure model performance. 
Results
Simulation of listwise deletion versus imputation
We study the effects of imputation using a "gold-standard" dataset derived from the complete cases of the P2APP dataset (see Table 7 ). To simulate the missingness present in the original dataset, we introduce missingness in the gold-standard dataset based on our MAR assumption and the missingness patterns observed in the P2APP dataset. We randomly split the drug-indication pairs into a training set (70%) and a testing set (30%), and use five different missing data approaches, as described in Supplementary Materials C, to generate complete training sets from the MAR training set. We use each imputed training set to build six different predictive models (PLR, RF, NN, GBT, SVM, and C5.0) according to the methodology outlined in Section 2. We repeat this experiment 100 times for robustness. For all six machine-learning algorithms, we find that gold-standard classifiers-that is, the models derived from complete data-consistently outperform their complete-case analysis and imputation counterparts. This is logical because useful information is invariably lost when we introduce missingness in the datasets. In contrast, complete-case analysis often leads to inferior performance. The AUCs of classifiers trained on complete-cases training sets tend to be smaller than those trained on imputed training sets. This suggests that imputation does indeed offer improved fit and predictive power over listwise deletion.
Overall, we find kNN imputation to be most compatible with our datasets. It provides the least biased imputations among all missing data methods (see Supplementary Materials E).
In particular, the combination of kNN imputation (k = 5) with RF gives one of the highest gold-standard testing set AUCs (0.81). We note a few other MI combinations that yield comparable or marginally better performance but focus on the 5NN-RF approach in subsequent analyses on the main datasets due to its ease of implementation and application.
We find that SVM has the worst performance among all machine-learning models. This is not surprising because SVMs are aimed only at learning binary classifiers, and do not generally produce good class probability estimates. Consequently, such models do not necessarily give high AUCs.
We also compare our approach with the ANDI algorithm (DiMasi et al., 2015) by applying a modified version of the index on oncology drugs in the gold-standard testing sets (see Supplementary Materials H for a more in-depth description). We find that our 5NN-RF model achieves significantly higher AUC than the modified ANDI, with an average improvement of 0.1 in AUC over 100 simulations (see Fig 7) . We believe that this gain can be attributed to a 
Predicting approvals
We analyze the two datasets (P2APP and P3APP) by first splitting each into a training set (70%) and a testing set (30%) randomly (pipeline drug-indication pairs are omitted since their outcomes have yet to be determined). Subsequently, we train 5NN-RF models for each scenario according to the methodology outlined in Section 2. We repeat this experiment 100 times for robustness. Table 9 summarizes the AUC performance metrics for the testing sets.
On average, we achieve 0.78 AUC for P2APP and 0.81 AUC for P3APP. The observed performance is essentially the MAR testing set AUC, since backfilling has already affected the datasets used. In Supplementary Materials E, we highlight the perils of relying on the MAR testing set for model validation, and suggest that the AUCs for the goldstandard and MCAR testing sets are more reflective of a classifier's real performance.
Unfortunately, we have access to neither the gold-standard nor the MCAR testing sets, because we do not know the true, underlying values of the missing features. However, our experiments indicate that the AUCs for the MAR and MCAR testing sets of the 5NN-RF combination are very close (a difference of 0.002 on average). This means that we may use the former, the only observed figure, as a reasonable estimate of the latter, which reflects real performance. Next, we train classifiers based on the union of the training and testing sets, and use them to generate predictions for pipeline drug-indication pairs. We generate predictions for P2APP using only information from phase 2 trials and for P3APP using only information from phase 3 trials. While we cannot compute AUC scores for these samples because their outcomes are still pending, we can compare their prediction scores with their development status at the time of this writing. These pipeline drug-indication pairs may still be in the same clinical stage (no change, i.e., phase 2 for P2APP; phase 3 for P3APP), be terminated (failed), or have progressed to higher phases (advanced). Table 10, and Table 11 summarize the distributions of pipeline prediction scores. We find that pairs that fail generally have lower scores than those that advance to later phases of development. In Fig 8, we observe peaks at the lower end of the score spectrum for failed pairs (red) for both datasets. In contrast, pairs that advance tend to have peaks at higher scores (green). We observe the same patterns when we disaggregate the distributions by indication groups: the green parts tend to cluster above the distribution median while the red parts cluster below. However, there are also some indication groups for which there are too few samples to make any useful remarks (e.g., hormonal products in P2APP). From Table   10 , we see that the average scores of failed pairs are indeed lower than those that advance (differences ranging from 0.05 to 0.15). In Table 11 , we bin drug-indication pairs that have new developments (whether failure or advancement) into four groupings, depending on their prediction scores. For each bin, we compute the proportion of samples that advance to later development stages. We find that the proportions generally increase with the score magnitude, suggesting that pairs with higher scores are more likely to advance than those with lower scores. We note that progress to later clinical stages does not always lead to To gain insight into the logic of our trained predictive models, we compute the average importance of features used in the 5NN-RF classifiers over all the experiments, and extract the top ten most informative variables. The RF classifier (Pedregosa et al., 2011) we used computes the importance of a variable by finding the decrease in node impurity for all nodes that split on that variable, weighted by the probability of reaching that node (as estimated by the proportion of samples reaching that node), averaged over all trees in the forest ensemble (Breiman, Friedman, Stone, & Olshen, 1984) . Table 12 summarizes the results. We find that trial outcome (whether the trial was completed with its primary endpoints met) and trial status (whether the trial was completed or terminated) have significant associations with success. These two features were consistently ranked the top two out of all variables and across both datasets. It is easy to imagine that a drug-indication pair whose trials were terminated has a low probability of success in terms of advancing from phases 2/3 to approval. In contrast, candidates that achieve positive outcomes certainly have a better shot at success. We also observe that prior approval of a drug has an effect on success for new indications or patient segmentation. It is plausible that developing an approved drug for a new indication has a greater likelihood of success than a new candidate.
In addition, trial characteristics such as accrual, duration, and the number of identified sites frequently appear in the top ten important variables. There are several possible explanations.
For example, trials that end quickly without achieving primary endpoints may undermine the likelihood of success, and drugs with trials that have small accrual-and thus low statistical power-may have a lower probability of being approved.
We also find sponsor track records-quantified by the number of past successful trials (trials that achieve positive results or meet primary endpoints)-to be a useful factor for prediction. This factor has not been considered in previous related studies, but the intuition for its predictive power is clear: strong track records are likely associated with greater expertise in drug development. Table 9 shows the results for selected indication groups. In general, we find specialized models to give poorer performance than general models. This is likely because the former are trained on less data, which makes them less accurate and more susceptible to overfitting.
We note that the approach adopted in this section-splitting drug-indication pairs into training and testing sets randomly without considering the dates of development-may be less than ideal because of look-ahead bias. For example, if the results of a 2008 trial are included in the training set for predicting the outcome of a 2004 development path for a drug-indication pair, our model will be using future information during validation, which can yield misleading and impractical inferences. To address this issue, in the next section we apply our machine-learning framework to time-series data using rolling windows that account for temporal ordering in the construction of training and testing sets. Although this process makes use of less data within each estimation window than when the entire dataset is used, it minimizes the impact of look-ahead bias and yields more realistic inferences. We study the effects of random splitting versus temporal ordering in Supplementary Materials J.
Predictions over time
Drug development has changed substantially over time, thanks to new scientific discoveries and technological improvements. To reflect these changes in our predictive analytics, we adopt a time series, walk-forward approach to create training and testing sets for each of the two datasets, P2APP and P3APP (see Fig 9) . We sample five-year rolling windows between We evaluate the resulting classifier by comparing its predictions with outcomes that are realized in the future (2009) (2010) (2011) (2012) (2013) (2014) (2015) . This rolling-window approach yields a total of eight overlapping training and testing periods where a new 5NN-RF model is trained for each period. The eighth testing period consists of drug-indication pairs in the pipeline at the time of snapshot of the databases. Unlike the first seven periods, their outcomes are still pending current development, and therefore we cannot compute a testing AUC for this window. Table 13, and Table 14 summarize the distributions of prediction scores for the P2APP and P3APP datasets. We observe very similar patterns to the static pipeline predictions above. The histograms, average scores, and binning of samples indicate that pairs that fail tend to have lower prediction scores than those that advance. This shows that our classifiers are indeed able to differentiate successful candidates. Table 13 . Distributions of prediction scores for all indication groups in aggregate (see Fig 11) . Advanced refers to progress to a higher phase from the original phase. Original phase for P2APP is phase 2; for P3APP is phase 3. Abbreviations: n: sample size; Avg: average; Sd: standard deviation; 5%: 5th percentile; 50%: median; 95%: 95th percentile. Table 15 summarizes the top ten most informative variables in the 5NN-RF classifiers over the eight rolling windows. We find them to be largely consistent with those observed in the static case: the trial outcome and trial status are significantly associated with success; trial characteristics (such as accrual, duration, and number of identified sites), sponsor track record, and drug medium appear frequently in both scenarios. As in the static case, we also train indication-group specific classifiers using rolling windows. specialized classifiers (e.g., the musculoskeletal indication group in P2APP). This is expected because models trained on small training sets are more susceptible to overfitting, especially when non-linear algorithms such as RF are used. In contrast, indication groups with larger sample sizes tend to give rise to rather good classifiers (e.g., anti-cancer in P2APP). For comparison, we disaggregate performance by indication group. We find that these classifiers do not lose out to their specialized counterparts. In fact, our results show that the former tend to exhibit more stable performance across the seven windows, particularly on indication groups with small sample sizes. We hypothesize that classifiers trained on all data benefit from having access to larger datasets with greater diversity, and are thus able to make more informed predictions. This suggests that it may be more appropriate to rely on general classifiers, rather than specialized ones, for predictions over time where samples are spread out over multiple windows, since further filtering by indication group results in even smaller sample sizes. Table 18 summarizes the results. We include only candidates that are still outstanding at the time of writing (neither discontinued nor approved). It is encouraging that many of these candidates (indicated in italics) have advanced beyond phase 2 testing since our analysis, indicating the predictive power of our models. We include an interactive version in Fig 12 where readers can filter our pipeline predictions by indication group and probability of approval. Ultimately, all biopharma stakeholders can use such scores to rank and evaluate the potential risks and rewards of drug candidates. 
Prediction
Discussion
Drug development is an extremely costly process and the accurate evaluation of a candidate drug's likelihood of approval is critical to the efficient allocation of capital. Historical successes and failures contain valuable insights on the characteristics of high-potential candidates. Unfortunately, such data are often incomplete due to partial reporting by investigators and developers. Most analytic methods require complete data, however, and prior studies on estimating approval rates and predicting approvals are typically based on a small number of examples that have complete information for just a few features.
In this paper, we extract two datasets, P2APP and P3APP, from Informa ® databases and apply 5NN statistical imputation to make efficient use of all available data. We use machinelearning techniques to train and validate our RF predictive models and achieve promising levels of predictive power for both datasets. When applied to pipeline drugs, we find that candidates with higher scores are indeed more likely to advance to higher clinical phases, indicating that our 5NN-RF classifiers are able to discriminate between high-and lowpotential candidates.
A time-series analysis of the datasets shows generally increasing trends in performance over five-year rolling windows from 2004 to 2014. We find that the classifiers' performance correlates well with the proportions of complete cases in the training sets: as completeness increases, the classifier learns better and achieves higher AUCs. This highlights the importance of data quality in building more accurate predictive algorithms for drug development. These results are promising and raise the possibility of even more powerful drug development prediction models with access to better quality data. This can be driven by programs such as Project Data Sphere (Green et al., 2015) and Vivli (Bierer, Li, Barnes, & Sim, 2016 ) that promote and facilitate public sharing of patient-level clinical trial data. Ultimately, such predictive analytics can be used to make more informed data-driven decisions in the risk assessment and portfolio management of investigational drugs at all clinical stages.
